Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Mar 3;12(3):e055821.
doi: 10.1136/bmjopen-2021-055821.

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Frédérique Berger  1 , Margaux Marce  2 , Suzette Delaloge  3 , Anne-Claire Hardy-Bessard  4 , Thomas Bachelot  5 , Ivan Bièche  6 , Anne Pradines  7   8 , Thibault De La Motte Rouge  9 , Jean-Luc Canon  10 , Fabrice André  11 , Laurent Arnould  12 , Florian Clatot  13 , Jérôme Lemonnier  14 , Sandrine Marques  14 , François-Clement Bidard  15   16 ; PADA-1 investigators
Collaborators, Affiliations
Clinical Trial

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Frédérique Berger et al. BMJ Open. .

Abstract

Introduction: The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. However, most patients receiving this combination will ultimately progress and require further therapies.Several studies have demonstrated that the onset of a ESR1 gene mutation lead to AIs resistance in the advanced setting. ESR1 mutations can be detected in circulating tumour DNA (ctDNA) using a digital PCR assay. Our study aims to prove the clinical efficacy of periodic monitoring for emerging or rise of ESR1 mutations in ctDNA to trigger an early change from AI plus palbociclib to fulvestrant plus palbociclib treatment while assessing global safety.

Methods: PADA-1 is a randomised, open-label, multicentric, phase III trial conducted in patients receiving AI and palbociclib as first line therapy for metastatic ER +HER2- breast cancer. 1000 patients will be included and treated with palbociclib in combination with an AI. Patients will be screened for circulating blood ESR1 mutation detection at regular intervals. Patients for whom a rising circulating ESR1 mutation is detected without tumour progression (up to N=200) will be randomised (1:1) between (1) Arm A: no modification of therapy; and (2) Arm B: palbociclib in combination with fulvestrant, a selective ER down-regulator. At tumour progression, an optional crossover will be offered to patients randomised in arm A. The coprimary endpoints are (1) Grade ≥3 haematological toxicities and their associations with baseline characteristics and (2) progression-free survival in randomised patients.

Ethics and dissemination: The study has been approved by the French medicines agency (ANSM) and by an ethics committee (ref 01/17_1 CPP Ouest-IV Nantes) in January 2017. The trial results will be published in academic conference presentations and international peer-reviewed journals.

Trial registration numbers: EudraCT: 2016-004360-18; NCT03079011.

Keywords: breast tumours; clinical trials; oncology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SD: reports grants and non-financial support from Pfizer, grants from Novartis, grants and non-financial support from AstraZeneca, grants and non-financial support from Roche Genentech, grants from Lilly, grants from Puma, grants from Myriad, grants from Orion, grants from Amgen, grants from Sanofi, grants from Genomic Health, grants from GE, grants from Servier, grants from MSD, grants from BMS, grants from Pierre Fabre, outside the submitted work. A-CH-B: reports personal fees from AstraZeneca, personal fees from Daiichi, personal fees from Clovis, personal fees from GSK, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche outside the submitted work. TB: reports personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Pfizer, personal fees from Seagen, outside the submitted work. TDLMR: reports grants, personal fees and non-financial support from Pfizer, grants and non-financial support from Novartis, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Roche Genentech, grants and non-financial support from MSD, personal fees and non-financial support from TESARO-GSK, personal fees from CLOVIS ONCOLOGY, personal fees from MYLAN, outside the submitted work. FA: reports grants from Roche, grants from AstraZeneca, grants from Daiichi Sankyo, grants from Pfizer, grants from Novartis, grants from Lilly, outside the submitted work. LA: report personal fees from Roche, personal fees from MSD, personal fees from AstraZeneca, personal fees fromBMS, outside the submitted work. FC: reports grants from AstraZeneca, grants, personal fees and non-financial support from Roche, personal fees from Lilly, personal fees and non-financial support from Merck Serono, personal fees and non-financial support from BMS, outside the submitted work. F-CB: reports grants from PFIZER, during the conduct of the study; grants, personal fees and non-financial support from PFIZER, grants, personal fees and non-financial support from NOVARTIS, personal fees from LILLY, personal fees and non-financial support from ROCHE, personal fees and non-financial support from AstraZeneca, personal fees from AMGEN, personal fees from SANOFI, personal fees from Radius, grants and personal fees from Seagen, granst from Prolynx outside the submitted work; In addition, F-CB has a patent ctDNA detection by ddPCR pending.

Figures

Figure 1
Figure 1
Study scheme. AI, aromatase inhibitor; ctDNA, circulating tumour DNA; PADA-1, Palbociclib and ctDNA for ESR1 mutation detection.
See this image and copyright information in PMC

References

    1. Andre F, Slimane K, Bachelot T, et al. . Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302–8. 10.1200/JCO.2004.08.095 - DOI - PubMed
    1. Cardoso F, Costa A, Norton L, et al. . ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (Abc2). The Breast 2014;23:489–502. 10.1016/j.breast.2014.08.009 - DOI - PubMed
    1. Cardoso F, Costa A, Senkus E, et al. . Correction to: 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Annals Oncol Off J Eur Soc Med Oncol 2017;28:3111 10.1093/annonc/mdx036 - DOI - PMC - PubMed
    1. Finn RS, Crown JP, Lang I, et al. . The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25–35. 10.1016/S1470-2045(14)71159-3 - DOI - PubMed
    1. Turner NC, Ro J, André F, et al. . Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209–19. 10.1056/NEJMoa1505270 - DOI - PubMed

Publication types

Associated data